Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression, and developmental events. The Histone Deacetylase 3 pipeline drugs market research report outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.
HDAC3 Pipeline Drugs Market by Key Therapy Areas
The key therapy areas in the HDAC3 pipeline drugs market are oncology, central nervous system, gastrointestinal, infectious disease, and musculoskeletal disorders.
HDAC3 Pipeline Drugs Market, by Therapy Areas
For more therapy area insights, download a free report sample
Key Mechanism of Actions in the HDAC3 Pipeline Drugs Market
The key mechanism of action in the HDAC3 pipeline drugs market is Histone Deacetylase 3 Inhibitor.
Key Routes of Administration in the HDAC3 Pipeline Drugs Market
The key routes of administration in the HDAC3 pipeline drugs market are oral and topical.
HDAC3 Pipeline Drugs Market, by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the HDAC3 Pipeline Drugs Market
The key molecule types in the HDAC3 pipeline drugs market are small molecule, synthetic peptide, and biologic.
HDAC3 Pipeline Drugs Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the HDAC3 Pipeline Drugs Market
Some of the key companies in the HDAC3 pipeline drugs market are Shenzhen Chipscreen Biosciences Co Ltd, 4D Pharma Plc, BioMarin Pharmaceutical Inc, Curis Inc, GNT Biotech and Medicals Corp, Kdac Therapeutics Inc, Medivir AB, Merck & Co Inc, Oceanyx Pharmaceuticals Inc, and OnKure Inc.
HDAC3 Pipeline Drugs Market, by Companies
To know more about the companies, download a free report sample
Histone Deacetylase 3 Pipeline Drugs Market Report Overview
| Key Therapy Areas | Oncology, Central Nervous System, Gastrointestinal, Infectious Disease, and Musculoskeletal Disorders |
| Key Mechanism of Actions | Histone Deacetylase 3 Inhibitor |
| Key Routes of Administration | Oral and Topical |
| Key Molecule Types | Small Molecule, Synthetic Peptide, and Biologic |
| Key Companies | Shenzhen Chipscreen Biosciences Co Ltd, 4D Pharma Plc, BioMarin Pharmaceutical Inc, Curis Inc, GNT Biotech and Medicals Corp, Kdac Therapeutics Inc, Medivir AB, Merck & Co Inc, Oceanyx Pharmaceuticals Inc, and OnKure Inc |
Scope
This report provides:
- A snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98).
- Reviews of Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects.
- Assessment of Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- Summarization of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98).
- Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
BioMarin Pharmaceutical Inc
Curis Inc
GNT Biotech and Medicals Corp
Kdac Therapeutics Inc
Medivir AB
Merck & Co Inc
Oceanyx Pharmaceuticals Inc
OnKure Inc
Shenzhen Chipscreen Biosciences Co Ltd
Shuttle Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Table of Contents
Frequently asked questions
-
What are the key therapy areas of the HDAC3 pipeline drugs market?
The key therapy areas in the HDAC3 pipeline drugs market are oncology, central nervous system, gastrointestinal, infectious disease, and musculoskeletal disorders.
-
What are the key mechanism of actions in the HDAC3 pipeline drugs market?
The mechanism of action in the HDAC3 pipeline drugs market is Histone Deacetylase 3 Inhibitor.
-
What are the key routes of administration in the HDAC3 pipeline drugs market?
The routes of administration in the HDAC3 pipeline drugs market are oral and topical.
-
What are the key molecule types in the HDAC3 pipeline drugs market?
The key molecule types in the HDAC3 pipeline drugs market are small molecule, synthetic peptide, and biologic.
-
Which are the key companies in the HDAC3 pipeline drugs market?
The key companies in the HDAC3 pipeline drugs market are Shenzhen Chipscreen Biosciences Co Ltd, 4D Pharma Plc, BioMarin Pharmaceutical Inc, Curis Inc, GNT Biotech and Medicals Corp, Kdac Therapeutics Inc, Medivir AB, Merck & Co Inc, Oceanyx Pharmaceuticals Inc, and OnKure Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Other Diseases reports